ArticleGynecologic oncology reports2026

Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience.

Naroa Amondarain Amenabar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.